Its too early to know if this will work but it does appear promising.  Tying in a protein found on HDL cholesterol (known as Apo E) with amyloid has resulted in a basic science experiment which shows real promise for Alzhiemer's disease treatment.  The Wall Street Journal featured an article showing that a compound known as bexarotene (safe for treating skin cancer) stimulated mice genetics to increase Apo E production. This was associated with increasing dissolving amyloid plaque in a mouse Alzhiemer's disease model and a sustained improvement in cognition function. Prior to the compound being given to the mice, they couldn't smell or make a nest (loss of smell is frequent in Alzhiemer's patients). Within 3 days they were making organized nests (normal behavior lost when they are demonstrating Alzheimer's disease). This research will lead to human dosing trials according to the article.
         This summer I attended an HDL class sponsored by the National Lipid Association and learned that there is a metabolic pathway whereby HDL cholesterol does affect amyloid and other neuroprotein metabolism. This article suggests that the Apo E protein found in HDL may be what regulates this.  I predict that we will learn over time that HDL cholesterol has many more functions than our current simplistic understanding about returning cholesterol from cells back to the liver--which in and of itself is very important for treating and preventing atherosclerosis.